Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology MarketSeeking Alpha • 03/17/26
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of RapamycinGlobeNewsWire • 03/16/26
Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit OrganizationsGlobeNewsWire • 03/10/26
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 03/02/26
Why Top 2% Palvella Therapeutics Is About To Blow Past Its 50-Day LineInvestors Business Daily • 02/24/26
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic MalformationsGlobeNewsWire • 02/24/26
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic MalformationsGlobeNewsWire • 02/23/26
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in PorokeratosisGlobeNewsWire • 02/02/26
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved TherapiesGlobeNewsWire • 01/09/26
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical AffairsGlobeNewsWire • 01/07/26
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of AngiokeratomasGlobeNewsWire • 12/16/25
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved TherapiesGlobeNewsWire • 12/15/25
Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/11/25
Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved TherapiesGlobeNewsWire • 11/05/25
Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025GlobeNewsWire • 11/04/25
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic MalformationsGlobeNewsWire • 10/13/25
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved TherapiesGlobeNewsWire • 09/24/25